Replacement of microglial cells using Clodronate liposome and bone marrow transplantation in the central nervous system of SOD1G93A transgenic mice as an in vivo model of amyotrophic lateral sclerosis

2012 ◽  
Vol 418 (2) ◽  
pp. 359-365 ◽  
Author(s):  
Jae Chul Lee ◽  
Jinsil Seong ◽  
Seung Hyun Kim ◽  
Se Jeong Lee ◽  
Yu Jin Cho ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Bone Marrow ◽  
Amyotrophic Lateral Sclerosis ◽  
Nervous System ◽  
Bone Marrow Transplantation ◽  
In Vivo Model ◽  
Clodronate Liposome ◽  
The Central Nervous System ◽  
Lateral Sclerosis

Origin and distribution of bone marrow-derived cells in the central nervous system in a mouse model of amyotrophic lateral sclerosis

Glia ◽  
2006 ◽  
Vol 53 (7) ◽  
pp. 744-753 ◽  
Author(s):  
Jennifer N. Solomon ◽  
Coral-Ann B. Lewis ◽  
Bahareh Ajami ◽  
Stephane Y. Corbel ◽  
Fabio M.V. Rossi ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Bone Marrow ◽  
Amyotrophic Lateral Sclerosis ◽  
Nervous System ◽  
Mouse Model ◽  
The Central Nervous System ◽  
Bone Marrow Derived Cells ◽  
Lateral Sclerosis

scholarly journals Endogenous Cu in the central nervous system fails to satiate the elevated requirement for Cu in a mutant SOD1 mouse model of ALS

Metallomics ◽  
2016 ◽  
Vol 8 (9) ◽  
pp. 1002-1011 ◽  
Author(s):  
J. B. Hilton ◽  
A. R. White ◽  
P. J. Crouch
Keyword(s):  
Central Nervous System ◽  
Amyotrophic Lateral Sclerosis ◽  
Nervous System ◽  
Mouse Model ◽  
Limited Capacity ◽  
Mutant Sod1 ◽  
The Central Nervous System ◽  
Sod1 Mouse ◽  
Lateral Sclerosis

It is unclear why ubiquitous expression of mutant SOD1 selectively affects the central nervous system in amyotrophic lateral sclerosis. Here we hypothesise that the central nervous system is primarily affected because, unlike other tissues, it has relatively limited capacity to satiate an increased requirement for Cu.

scholarly journals Mantle Cell Lymphoma recurrence and involvement of the central nervous system after bone marrow transplantation: case report.

2021 ◽  
Author(s):  
Rafael Bragança Rodrigues Matias ◽  
Bruna Cardoso de Mattos Boccalini ◽  
Renata de Oliveira Costa ◽  
Maria Fernanda Mélega Mingossi
Keyword(s):  
Central Nervous System ◽  
Bone Marrow ◽  
Nervous System ◽  
Case Report ◽  
Bone Marrow Transplantation ◽  
Mantle Cell Lymphoma ◽  
Marrow Transplantation ◽  
Cell Lymphoma ◽  
Mantle Cell ◽  
The Central Nervous System

Introduction: Mantle cell lymphoma (MCL) is a subtype of uncommon nonHodgkin lymphoma. The involvement of the central nervous system (CNS) is uncommon in the course of the disease. Objective: To report a case of recurrence of MCL in the CNS as the first manifestation, after chemotherapy and bone marrow transplantation. Case report: Male patient, 49 years old, with no previous comorbidities diagnosed with stage IV MCL (bone marrow), submitted to chemotherapy and autologous transplantation. After two years, he sought out the neurology clinic with a complaint of blurred vision. Neurological examination: without motor deficit; bilateral partial ptosis, bilateral divergent strabismus, tongue shift to the right. CSF with 230 leukocytes/mm³, 70% of lymphocytes, glucose of 71 mg /dl and protein of 85 mg /dl; Skull MRI demonstrated bilateral and symmetrical enhancement of segments of the cisterns of the optic and oculomotor nerves; Trigeminal, facial, vestibulocochlear and glossopharyngeal, vagus and accessory nerves more exuberant on the left. CSF immunophenotyping showed CD19, CD5 and Kappa positive monoclonal, compatible with MCL recurrence. Intrathecal and systemic chemotherapy with methotrexate were initiated. Discussion: Risk of recurrence of MCL and infiltration of the CNS is uncommon (3.9 - 5%). The patient did not show any signs of systemic involvement, only the neurological findings, which is atypical since the neurological presentation is more associated with recurrence of MCL with a course of systemic findings. Conclusion:The authors point out that in patients with treated MCL who have neurological manifestations without systemic findings, tumor recurrence should be considered.

Sign in / Sign up

Export Citation Format

Share Document